[C#289:Novartis AG] is partnering with [C#24062:Lindy Biosciences] to make biologics normally available only as intravenous injections suitable for subcutaneous self-administration, which the companies said would improve outcomes as well as compliance among patients. For Novartis, it shows the company is interested in making its biologics – especially monoclonal antibodies – easier for patients to use, but is also taking a different tack from other pharma companies that have created subcutaneous versions of their products.
Raleigh, NC-based Lindy said 28 August that it entered into the licensing and collaboration agreement with the Swiss drug maker...
